Phase 2 N=30 Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients
Breast Neoplasm
Primary: Percentage of Subjects Able to Complete > 85% of the Planned Dose on Schedule — 60 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=20 Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer
HER2-Positive Early Stage Breast Cancer
Primary: Number of Participants Who Are Able to Complete THL (Paclitaxel, Trastuzumab, and Lapatinib) Without a Dose Delay or Reduction, Grade 3 or Greater QTc Prolongation — 16…
Phase 2 N=32 Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.
Breast Cancer
Primary: Percent of Patients Who Achieve a pCR — 19; 2; 0; 0 Participants
Phase 2 N=20 Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery
HER2 Positive Breast Carcinoma · Stage I Breast Cancer AJCC v7 · Stage IA Breast Cancer AJCC v7
Primary: Number Participants With Neutropenia, Graded According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version (v)4.03 — 2…
Phase 2 N=493 Adj TC + Herceptin Early Stage Breast Cancer
Breast Cancer
Primary: Disease-free Survival (DFS) Rate at 2 Years in TOP2A-amplified and in TOP2A-nonamplified HER2+ ESBC Patients Treated With TC+H. — 0.978; 0.979 probability of…
Phase 2 N=112 Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery
Breast Cancer · Cardiac Toxicity
Primary: Number of Patients With Congestive Heart Failure (CHF) While on Active Treatment — 0 participants
Phase 2 N=58 Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer
Breast Cancer
Primary: Pathologic Complete Response (pCR) — 27 participants
Phase 2 N=102 Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients
Breast Cancer
Primary: Complete Pathological Response (pCR) Rate in Breast and Axilla According to the Miller&Payne Criteria (G5-A and G5-D). — 23.5; 47.9 percentage of participants with pCR
Phase 2 N=30 Docetaxel, Carboplatin, Trastuzumab, and Lapatinib in Treating Patients With Early Stage Breast Cancer
Breast Cancer
Primary: Proportion of Patients Experiencing Grade 3 or 4 Diarrhea as Measured by NCI CTCAE v3.0 — 43 percentage of patients
Phase 2 N=37 Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer
Breast Cancer · Invasive Breast Cancer
Primary: Change in Baseline of Cancer Cell Protein Levels of Human Epidermal Growth Factor Receptor (HER) Family Members (HER1-4) Following Neoadjuvant Endocrine Therapy. — 1…
Phase 2 N=21 Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer
Breast Cancer · Metastatic Breast Cancer
Primary: Percentage of Participants With Pathologic Complete Response (pCR) — 38.9 percentage of participants
Phase 2 N=100 Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients
Breast Cancer
Primary: Invasive Disease-free Survival (DFS) — 42; 47 Participants
Phase 2 N=82 Multimodality Treatment for Women With Stage II, Stage III, or Stage IV Breast Cancer
Breast Cancer
Primary: Cardiac Toxicity of Weekly Taxol Given With Weekly Herceptin When Delivered Immediately Following Four Cycles of Standard Dose AC. — 1; 8; 3; 11 Participants
Phase 2 N=141 Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer
Breast Cancer
Primary: Pathologic Complete Response in Breast and Axillary Lymph Nodes. — 16; 14; 21; 5 Participants
Phase 2 N=83 Neoadjuvant Treatment With Nab-paclitaxel for Patients With Stage II and III Luminal Breast Cancer
Breast Cancer
Primary: The Residual Cancer Burden Grade III (RCB-III). — 23; 37; 14; 6 Participants
Phase 3 N=329 Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel
Breast Cancer
Primary: Percentage of Participants With Total Pathologic Complete Response (tpCR) as Assessed by the Independent Review Committee (IRC) — 39.3; 21.8 percentage of participants…
N/A N=111 A Retrospective Observational Study of Patients With Early-stage HER2-positive Breast Cancer, Treated With Neratinib
Breast Cancer · Adjuvant Therapy · HER2-positive Breast Cancer
Primary: Description of Age — 49.2 years
Phase 3 N=652 Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer
Breast Cancer
Primary: Progression Free Survival (PFS) at the Time of Primary Results — 8.97; 11.30; 9.13; 13.63 Months — p=0.0010
Phase 2 N=95 Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer
Breast Cancer
Primary: Number of Patients Who Completed All Planned Therapy — 45 participants
Phase 2 N=406 Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Breast Cancer · Carcinoma of the Breast
Primary: 3-year Disease Free Survival (DFS) Rate — 0.987 proportion of participant
Phase 2 N=32 Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression
Breast Cancer
Primary: Pathologic Complete Response — 26 percentage of participants
Phase 2 N=70 Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility
Breast Cancer
Primary: Cardiac Saftey — 68; 67; 66; 65 percentage of LVEF
Phase 2 N=27 Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression
Breast Cancer
Primary: The Objective Response Rate as Defined as Stable Disease or the Rate of Complete and Partial Responses Determined on Two Consecutive Occasions Greater Than or Equal to 4…
Phase 2 N=27 Phase II Neoadjuvant Trial of Trastuzumab in Combination With Dose-Dense ABI-007 (Abraxane™)
Breast Cancer
Primary: Number of Participants With Complete Pathologic Response. — 13 participants
Phase 2 N=65 Lapatinib and Trastuzumab With or Without Endocrine Therapy
Breast Cancer
Primary: Pathologic Assessment After Study Treatment — 18; 16; 30 participants
Phase 2 N=225 A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer
Breast Cancer
Primary: Safety: Percentage of Participants With Symptomatic Cardiac Events as Assessed by the Investigator — 0; 2.7; 1.3 percentage of participants
Phase 2 N=26 Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients
Breast Cancer
Primary: Progression-free Survival (PFS) and to Evaluate Safety of the Trastuzumab, Bevacizumab and Docetaxel Regimen. — 14.3 months
Phase 2 N=144 A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Breast Neoplasms
Primary: Stage 1: Percentage of Participants With Objective Response — 10.0; 10.0; 26.9; 16.7 percentage of participants
Phase 2 N=60 Neoadjuvant Carboplatin, Weekly Abraxane and Trastuzumab in HER2+ Breast Cancer
Breast Cancer
Primary: Number of Patients With Complete Pathologic Response Rate, Observed Following Treatment With q3week Carboplatin, Weekly Abraxane and Weekly Trastuzumab in Resectable and…
Phase 2 N=81 Preoperative Herceptin/Navelbine Versus Taxotere/Carboplatin/Herceptin in HER-2 Positive Breast Cancer
Breast Cancer
Primary: Pathological Complete Response After Preoperative Therapy With Herceptin/Navelbine Versus Taxotere/Carboplatin/Herceptin in Patients With HER-2 Positive Early Breast…